NEW YORK, Nov. 16, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Clovis Oncology, Inc. ("Clovis" or the "Company") (NasdaqGS: CLVS -News). Such investors are advised to contact Peretz Bronstein or his investor relations coordinator Eitan Kimelman at [email protected] or 212-697-6484.
The investigation concerns whether Clovis and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On November 16, 2015, Clovis revealed that the efficacy of its lead drug candidate rociletinib, as measured by tumor shrinkage response rates in lung cancer patients, was actually far lower than previously presented. Clovis disclosed that potential approval of its lung cancer treatment rociletinib will likely be delayed because the FDA has asked for more data concerning the use of two different dosages and their response rates.
Following this news, Clovis stock fell $69.19 or over 69% to close at $30.24 on November 16, 2015.
If you are aware of any facts relating to this investigation, or purchased shares of Clovis, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC